A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Conditions:   Leukemia;   Lymphoma;   Lymphoma, B-Cell Intervention:   Biological: CAR T-Cell Infusion Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials